BI 90571 status
Looks like they've enrolled around 33 patients up to Jan 22, so it could be a while yet before the phase 1 reads out if they are targeting 140 patients.
"In preclinical assays, BI 905711 demonstrated a potency shift of ̃1000 fold versus the 1st-generation TRAILR2 agonist lexatumumab. BI 905711 induced apoptosis in CDH17-positive tumor cells in vitro, impaired tumor growth in pt-derived colorectal cancer (CRC) xenografts, and no hepatotoxicity was observed."
I think if you were looking at how BI is going to assess whether CDH-17 is a promising target, the above statement speaks volumes. By introducing bi-specific CDH-17 BI 905711, they were able to not only improve relative potency (vs 1st gen lexatumumab), they saw safety improvements as well (1st gen lexatumumab had high frequency of hepatotoxicity).But what CHM have is something a step up from what Boehringer Ingelheim appear to have. Nowhere have I read that BI 905711 had succeeded in total cancer cell eradication, which is what CHM's CDH-17 3rd gen CAR-T has achieve in vitro.
We can see that U Penn may well have achieved something on-par with Boehringer Ingelheim with its 2nd gen CDH17 CAR-T (note there was some anti-tumor activity observed vs yellow control line), but it was not until U Penn created the 3rd gen CDH17 CAR-T did it achieve the remarkable result of total eradication of tumor cells with no relapse.
That is a totally new benchmark in CDH-17, despite CHM not being the first mover.. it is IMO in the box seat.
(20min delay)